BioCentury
ARTICLE | Clinical News

AVP-786: Phase II started

September 15, 2014 7:00 AM UTC

Avanir began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily oral AVP-786 for 10 weeks in about 200 patients with MDD who had an inadequate response to antidepressant t...